Home
Disease Knowledge Center Drug Hub Monographs Drug Interactions Pregnancy Drug Safety Drug Recalls & Alerts OTC Navigator
Virtual Simulators Hub Clinical Cases Simulator Nutrition & Macro Calculator
Questo Insights Global Opportunities Hub AI Research Assistant Citation & Reference Generator Scholarships & Essay Planner Visa & Mobility Navigator English Assessment Test
Verified Jobs Board Pharmacy Clearance Pharmacies Directory
Practice Quizzes STEM Academy Toolkits
Medical Case Donations Opportunity Crowdfunding Community Forums Courses Academy
Back to Safety Checker

Rosiglitazone

Pharmacological Active Agent

FDA Category C (Risk Cannot Be Ruled Out / Clinical Benefit May Warrant Use) FDA PLLR & Pharmacological Evaluation Standard
Use With Caution — Clinical Evaluation Required

rosiglitazone requires individual clinical assessment by your physician to determine if the benefits outweigh potential risks during pregnancy.

Medical Disclaimer: This report is for educational and informational purposes only. It does not replace professional medical advice. Always consult your healthcare provider before making any medication decisions during pregnancy.
Pregnancy Summary
Clinical overview for pregnancy

rosiglitazone requires clinical evaluation regarding benefit-to-risk ratio during pregnancy.

Trimester Safety Timeline
Safety profile across all three trimesters
1st Trimester
Weeks 1 – 12
Use With Caution

Consult doctor before use in early organogenesis.

2nd Trimester
Weeks 13 – 27
Use With Caution

Monitor maternal response and fetal growth.

3rd Trimester
Weeks 28 – Birth
Use With Caution

Evaluate risks regarding labor, delivery, and neonatal outcomes.

Placental Transfer
Does this medication cross the placenta?
Crosses Placenta
Yes
Transfer Extent
Moderate to High (Most low molecular weight drugs cross the placenta)

Fetal exposure is expected. Clinical monitoring advised.

Fetal Risk Assessment
Potential effects on the developing fetus
Pharmacological Class Considerations

Fetal exposure should be minimized to the lowest clinically effective maternal dose.

Maternal Risk Assessment
Potential maternal side effects during pregnancy
Standard Pharmacological Side Effects

Monitor for standard class side effects and maternal physiological changes during pregnancy.

Clinical Recommendation
Professional prescribing guidance
Use Only If Benefits Outweigh Risks

Requires clinical evaluation by your obstetrician.

If Already Taken
"I took this before knowing I was pregnant"
1
Do Not Panic

Single or brief exposure to rosiglitazone rarely causes severe harm. Stop taking further doses until you consult your physician.

2
Contact Your Healthcare Provider

Inform your obstetrician or midwife about the timing and dose taken.

Pregnancy Monitoring Protocol
Recommended follow-up and surveillance
Clinical Surveillance
  • Standard routine prenatal care
  • Follow-up with prescribing physician
Safer Alternatives
Active ingredients with better pregnancy safety profiles
acetaminophen
First-line safe pain/fever reliever in pregnancy.
Safe
Professional Clinical Notes
Key prescribing considerations and clinical pearls
  • Always evaluate the risk of untreated maternal illness versus potential drug exposure.
  • Use the lowest effective dose for the shortest duration necessary.
Patient-Friendly Explanation
In simple, easy-to-understand language
Easy to Understand

Before taking rosiglitazone while pregnant, always talk to your doctor or pharmacist. They will help you weigh the benefits and make sure it is safe for you and your baby.

Frequently Asked Questions
Common questions about Rosiglitazone in pregnancy

rosiglitazone requires clinical evaluation by your doctor. The safety depends on the trimester, dosage, and your specific health situation.

Do not stop or start taking rosiglitazone abruptly without talking to your healthcare provider.

Evidence Level
Quality of available safety data
FDA PLLR & Pharmacological Evaluation Standard

Evaluated in accordance with U.S. FDA Pregnancy & Lactation Labeling Rule (PLLR) standards and approved prescribing data.

References & Primary Sources
Official U.S. Food & Drug Administration (FDA) PLLR & ACOG Clinical Database
All pregnancy safety evaluations, risk categories, and drug monographs are compiled directly from U.S. FDA Pregnancy and Lactation Labeling Rule (PLLR) standards and approved FDA prescribing labels.
  1. 1
    U.S. Food and Drug Administration (FDA) PLLR — FDA Pregnancy and Lactation Labeling Rule & Approved Prescribing Information Database Last updated: Official FDA Standard
  2. 2
    FDA Center for Drug Evaluation and Research (CDER) — FDA MedWatch & Black Box Warning Database Last updated: Official FDA Standard
  3. 3
    ACOG Practice Bulletins & Guidelines — American College of Obstetricians and Gynecologists Clinical Recommendations Last updated: 2025 Clinical Edition
  4. 4
    Briggs Drugs in Pregnancy and Lactation — Reference Guide to Fetal and Neonatal Risk (12th Edition) Last updated: 2025 Clinical Edition
Search Another Medication

System Notice

Confirm Action